Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 49

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Role of Ursodeoxycholic Acid in Treating and Preventing Idiosyncratic Drug-Induced Liver Injury. A Systematic Review

Robles-Díaz, Mercedes, Nezic, Lana, Vujic-Aleksic, Vesna, Björnsson, Einar S. · 2021 · Frontiers in Pharmacology

Abstract

Introduction: Treatment is generally not available for drug-induced liver injury (DILI) patients except in some specific circumstances. The management of DILI is based on the withdrawal of the responsible drug and monitoring the patients and only a few patients need to be referred to a transplant center. Some studies on the role of ursodeoxycholic acid (UDCA) in DILI have been published. The aim of this study was to perform a systematic review of the role of UDCA in the treatment and prevention of DILI. Methods: A search was undertaken in PubMed, with the key words ursodeoxycholic acid, drug-induced liver injury and hepatotoxicity following the PRISMA guidelines. Results: A total of 33 publications were identified: 25 case reports and 8 case series. In 18 of the 25 cases reports (22 patients), authors reported improvement of liver injury associated with UDCA therapy whereas 7 case reports did not show clinical or biochemical improvement after UDCA treatment. There were 4 studies evaluating the role of UDCA in the treatment of DILI, three prospective (one being a clinical trial) and one retrospective studies. Three studies observed liver profile improvements associated with UDCA. In addition, four studies evaluated UDCA in the prevention of DILI: one pilot study, two randomized clinical trials (RCT) and one retrospective study. Three of these studies observed a lower percentage of patients with an increase in transaminases in the groups that used UDCA for DILI prevention. Conclusion: According to available data UDCA seems to have some benefits in the treatment and prevention of DILI. However, the design of the published studies does not allow a firm conclusion to be drawn on the efficacy of UDCA in DILI. A well designed RCT to evaluate the role of UDCA in DILI is needed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2021.744488

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 56

  1. Abeles, 2020, Androgenic Anabolic Steroid-Induced Liver Injury: Two Case Reports Assessed for Causality by the Updated Roussel Uclaf Causality Assessment Method (RUCAM) Score and a Comprehensive Review of the Literature, BMJ Open Gastroenterol., 7, 7, 10.1136/bmjgast-2020-000549 · DOI
  2. Agca, 2004, Ursodeoxycholic Acid for Terbinafine-Induced Toxic Hepatitis, Ann. Pharmacother., 38, 1088, 10.1345/aph.1D420 · doi:10.1345/aph.1d420
  3. Ahmed, 2020, Delayed Presentation of Drug-Induced Hepatic Injury, Cureus, 12, e9713, 10.7759/cureus.9713 · doi:10.7759/cureus.9713
  4. Aithal, 2011, Case Definition and Phenotype Standardization in Drug-Induced Liver Injury, Clin. Pharmacol. Ther., 89, 806, 10.1038/clpt.2011.58 · DOI · Paper page
  5. Alhumaidha, 2014, Protective Effects of Ursodeoxycholic Acid on Ceftriaxone-Induced Hepatic Injury in Rats, Bull. Fac. Pharm. Cairo Univ., 52, 45, 10.1016/j.bfopcu.2014.02.002 · doi:10.1016/j.bfopcu.2014.02.002
  6. Ali, 2020, Ursodeoxycholic Acid Abrogates Gentamicin-Induced Hepatotoxicity in Rats: Role of NF-κB-p65/TNF-α, Bax/Bcl-xl/Caspase-3, and eNOS/iNOS Pathways, Life Sci., 254, 117760, 10.1016/j.lfs.2020.117760 · DOI
  7. Amaral, 2007, p53 Is a Key Molecular Target of Ursodeoxycholic Acid in Regulating Apoptosis, J. Biol. Chem., 282, 34250, 10.1074/jbc.M704075200 · DOI
  8. Asgarshirazi, 2015, Ursodeoxycholic Acid Can Improve Liver Transaminase Quantities in Children with Anticonvulsant Drugs Hepatotoxicity: A Pilot Study, Acta Med. Iran, 53, 351
  9. Ashby, 2018, Review Article: Therapeutic Bile Acids and the Risks for Hepatotoxicity, Aliment. Pharmacol. Ther., 47, 1623, 10.1111/apt.14678 · DOI
  10. Bandiera, 2015, miR-122--a Key Factor and Therapeutic Target in Liver Disease, J. Hepatol., 62, 448, 10.1016/j.jhep.2014.10.004 · DOI · Paper page
  11. Bordbar, 2018, Effect of Ursodeoxycholic Acid and Vitamin E in the Prevention of Liver Injury from Methotrexate in Pediatric Leukemia, Turk J. Gastroenterol., 29, 203, 10.5152/tjg.2018.17521 · doi:10.5152/tjg.2018.17521
  12. Castro, 2005, A Distinct Microarray Gene Expression Profile in Primary Rat Hepatocytes Incubated with Ursodeoxycholic Acid, J. Hepatol., 42, 897, 10.1016/j.jhep.2005.01.026 · DOI
  13. Chawla, 2000, Rapidly Progressive Cholestasis: An Unusual Reaction to Amoxicillin/clavulanic Acid Therapy in a Child, J. Pediatr., 136, 121, 10.1016/S0022-3476(00)90064-7 · DOI
  14. Chen, 2011, The Protective Effects of Ursodeoxycholic Acid on Isoniazid Plus Rifampicin Induced Liver Injury in Mice, Eur. J. Pharmacol., 659, 53, 10.1016/j.ejphar.2011.03.007 · DOI
  15. Cicognani, 1996, Flutamide-induced Toxic Hepatitis. Potential Utility of Ursodeoxycholic Acid Administration in Toxic Hepatitis, Dig. Dis. Sci., 41, 2219, 10.1007/BF02071403 · DOI
  16. Danan, 1993, Causality Assessment of Adverse Reactions to Drugs--I. A Novel Method Based on the Conclusions of International Consensus Meetings: Application to Drug-Induced Liver Injuries, J. Clin. Epidemiol., 46, 1323, 10.1016/0895-4356(93)90101-6 · DOI · Paper page
  17. El Khoury, 2017, Severe Cholestasis and Bile Cast Nephropathy Induced by Anabolic Steroids Successfully Treated with Plasma Exchange, Case Rep. Med., 2017, 4296474, 10.1155/2017/4296474 · doi:10.1155/2017/4296474
  18. Fernandes, 2019, Kratom-Induced Cholestatic Liver Injury and its Conservative Management, J. Investig. Med. High Impact Case Rep., 7, 2324709619836138, 10.1177/2324709619836138 · DOI
  19. Gallelli, 2009, Hepatotoxicity Induced by Methimazole in a Previously Healthy Patient, Curr. Drug Saf., 4, 204, 10.2174/157488609789006912 · DOI
  20. Goossens, 2013, Severe Immune-Mediated Drug-Induced Liver Injury Linked to Ibandronate: A Case Report, J. Hepatol., 59, 1139, 10.1016/j.jhep.2013.06.003 · DOI
  21. Ito, 2014, Combined Use of Ursodeoxycholic Acid and Bosentan Prevents Liver Toxicity Caused by Endothelin Receptor Antagonist Bosentan Monotherapy: Two Case Reports, J. Med. Case Rep., 8, 250, 10.1186/1752-1947-8-250 · DOI
  22. Jorge, 2005, Hepatotoxicity Associated with the Ingestion of Centella asiatica, Rev. Esp Enferm Dig., 97, 115, 10.4321/S1130-01082005000200006 · DOI
  23. Katsinelos, 2000, Ursodeoxycholic Acid (UDCA) for the Treatment of Amoxycillin-Clavulanate Potassium (Augmentin)-Induced Intra-hepatic Cholestasis: Report of Two Cases, Eur. J. Gastroenterol. Hepatol., 12, 365, 10.1097/00042737-200012030-00017 · DOI
  24. Kim, 2019, Ursodeoxycholic Acid Exerts Hepatoprotective Effects by Regulating Amino Acid, Flavonoid, and Fatty Acid Metabolic Pathways, Metabolomics, 15, 30, 10.1007/s11306-019-1494-5 · DOI
  25. Kojima, 2002, Clinical Utility of Ursodeoxycholic Acid in Preventing Flutamide-Induced Hepatopathy in Patients with Prostate Cancer: A Preliminary Study, Int. J. Urol., 9, 42, 10.1046/j.1442-2042.2002.00412.x · doi:10.1046/j.1442-2042.2002.00412.x
  26. Krishnan, 2009, Prolonged Intrahepatic Cholestasis and Renal Failure Secondary to Anabolic Androgenic Steroid-Enriched Dietary Supplements, J. Clin. Gastroenterol., 43, 672, 10.1097/MCG.0b013e318188be6d · DOI
  27. Kurokawa, 2019, Cholestatic Liver Injury Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma, Intern. Med., 58, 3283, 10.2169/internalmedicine.2591-18 · DOI
  28. Lang, 2019, Ursodeoxycholic Acid Attenuates Hepatotoxicity of Multidrug Treatment of Mycobacterial Infections: A Prospective Pilot Study, Int. J. Mycobacteriol, 8, 89, 10.4103/ijmy.ijmy_159_18 · DOI · Paper page
  29. Lapenna, 2002, Antioxidant Properties of Ursodeoxycholic Acid, Biochem. Pharmacol., 64, 1661, 10.1016/S0006-2952(02)01391-6 · DOI
  30. Lee, 2017, Exploration of Biomarkers for Amoxicillin/Clavulanate-Induced Liver Injury: Multi-Omics Approaches, Clin. Transl Sci., 10, 163, 10.1111/cts.12425 · DOI
  31. Li, 2019, Stevens-Johnson Syndrome and Acute Vanishing Bile Duct Syndrome after the Use of Amoxicillin and Naproxen in a Child, J. Int. Med. Res., 47, 4537, 10.1177/0300060519868594 · DOI
  32. Li, 2020, Ursodeoxycholic Acid Protects against Arsenic Induced Hepatotoxicity by the Nrf2 Signaling Pathway, Front. Pharmacol., 11, 594496, 10.3389/fphar.2020.594496 · DOI
  33. Lindor, 2009, High-dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis, Hepatology, 50, 808, 10.1002/hep.23082 · DOI · Paper page
  34. Ljubuncic, 2000, Ursodeoxycholic Acid Suppresses Extent of Lipid Peroxidation in Diseased Liver in Experimental Cholestatic Liver Disease, Dig. Dis. Sci., 45, 1921, 10.1023/A:1005615306596 · DOI
  35. Miura, 2001, Functional Modulation of the Glucocorticoid Receptor and Suppression of NF-kappaB-dependent Transcription by Ursodeoxycholic Acid, J. Biol. Chem., 276, 47371, 10.1074/jbc.M107098200 · DOI
  36. Mohammed Saif, 2012, Hepatoprotective Efficacy of Ursodeoxycholic Acid in Pediatrics Acute Lymphoblastic Leukemia, Pediatr. Hematol. Oncol., 29, 627, 10.3109/08880018.2012.713083 · DOI
  37. Neeman, 2019, Acute Liver Injury Leading to Death in the Setting of Brentuximab Vedotin Monotherapy, Leuk. Lymphoma, 60, 2283, 10.1080/10428194.2019.1579321 · doi:10.1080/10428194.2019.1579321
  38. O’Brien, 1996, Drug-induced Vanishing Bile Duct Syndrome: Response to Ursodiol, Am. J. Gastroenterol., 91, 1456
  39. Onishi, 2020, Ursodeoxycholic Acid and Bezafibrate Were Useful for Steroid-Refractory, Immune-Related Hepatitis: a Case Report, J. Med. Case Rep., 14, 230, 10.1186/s13256-020-02541-3 · DOI
  40. Paumgartner, 2004, Mechanisms of Action and Therapeutic Efficacy of Ursodeoxycholic Acid in Cholestatic Liver Disease, Clin. Liver Dis., 8, 67, 10.1016/S1089-3261(03)00135-1 · DOI · Paper page
  41. Piotrowicz, 1995, Ursodeoxycholic Acid for the Treatment of Flucloxacillin-Associated Cholestasis, J. Hepatol., 22, 119, 10.1016/0168-8278(95)80272-X · DOI
  42. 2006, Current Trends in BSEP Inhibition and Perturbation to Bile Acid Homeostasis as Mechanisms of Drug-Induced Liver Injury, 2006
  43. Reuben, 2016, Outcomes in Adults with Acute Liver Failure between 1998 and 2013: An Observational Cohort Study, Ann. Intern. Med., 164, 724, 10.7326/M15-2211 · DOI · Paper page
  44. Rudic, 2012, Ursodeoxycholic Acid for Primary Biliary Cirrhosis, Cochrane Database Syst. Rev., 12, CD000551, 10.1002/14651858.cd000551.pub3 · DOI · Paper page
  45. Saito, 2016, Effectiveness of Hepatoprotective Drugs for Anti-tuberculosis Drug-Induced Hepatotoxicity: A Retrospective Analysis, BMC Infect. Dis., 16, 668, 10.1186/s12879-016-2000-6 · doi:10.1186/s12879-016-2000-6
  46. Salmon, 2001, Ursodeoxycholic Acid and Prevention of Tacrine-Induced Hepatotoxicity: a Pilot Study, Therapie, 56, 29
  47. Sánchez-Osorio, 2008, Anabolic-androgenic Steroids and Liver Injury, Liver Int., 28, 278, 10.1111/j.1478-3231.2007.01579.x · DOI
  48. Singh, 1996, Extreme Hyperbilirubinemia Associated with the Use of Anabolic Steroids, Health/nutritional Supplements, and Ethanol: Response to Ursodeoxycholic Acid Treatment, Am. J. Gastroenterol., 91, 783
  49. Smith, 2005, Vanishing Bile Duct Syndrome: Amoxicillin-Clavulanic Acid Associated Intra-hepatic Cholestasis Responsive to Ursodeoxycholic Acid, J. Pediatr. Gastroenterol. Nutr., 41, 469, 10.1097/01.mpg.0000178086.44155.73 · DOI
  50. Stępień, 2015, Severe Intrahepatic Cholestasis and Liver Failure after Stanozolol Usage - and Review of the Literature, Clin. Exp. Hepatol., 1, 30, 10.5114/ceh.2015.51376 · doi:10.5114/ceh.2015.51376
  51. Stine, 2016, Current and Future Directions in the Treatment and Prevention of Drug-Induced Liver Injury: A Systematic Review, Expert Rev. Gastroenterol. Hepatol., 10, 517, 10.1586/17474124.2016.1127756 · DOI · Paper page
  52. Studniarz, 2012, Amoxicillin/clavulanic Acid-Induced Cholestatic Liver Injury after Pediatric Liver Transplantation, Ann. Transpl., 17, 128, 10.12659/aot.882646 · DOI
  53. Tejedor-Tejada, 2019, Hepatobiliary and Pancreatic: Sertraline-Induced Vanishing Bile Duct Syndrome Treated with Plasmapheresis, J. Gastroenterol. Hepatol., 34, 488, 10.1111/jgh.14503 · doi:10.1111/jgh.14503
  54. Uraz, 2008, Role of Ursodeoxycholic Acid in Prevention of Methotrexate-Induced Liver Toxicity, Dig. Dis. Sci., 53, 1071, 10.1007/s10620-007-9949-3 · DOI
  55. Vincent, 2014, Recent Advances in Understanding of NASH: MicroRNAs as Both Biochemical Markers and Players, Curr. Pathobiol Rep., 2, 109, 10.1007/s40139-014-0049-8 · DOI
  56. Wree, 2011, Steroid and Ursodesoxycholic Acid Combination Therapy in Severe Drug-Induced Liver Injury, Digestion, 84, 54, 10.1159/000322298 · DOI · Paper page

Cited by

See all 49

Metadata

Authors
Robles-Díaz, M., Nezic, L., Vujic-Aleksic, V., & Björnsson, E. S.
Venue
Frontiers in Pharmacology
Published
2021-10-27
Volume
12
ISSN
1663-9812
Cited by
49
References
9
Funders
  • Instituto de Salud Carlos III
  • Consejería de Salud y Familias, Junta de Andalucía
  • Agencia Española de Medicamentos y Productos Sanitarios
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
  • European Cooperation in Science and Technology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.